Display options
Cite
Fu J, Tomlinson G, Feig DS. Increased risk of major congenital malformations in early pregnancy use of angiotensin-converting-enzyme inhibitors and angiotensin-receptor-blockers: a meta-analysis. Diabetes Metab Res Rev. 2021;37(8):e3453doi: 10.1002/dmrr.3453.
Fu, J., Tomlinson, G., & Feig, D. S. (2021). Increased risk of major congenital malformations in early pregnancy use of angiotensin-converting-enzyme inhibitors and angiotensin-receptor-blockers: a meta-analysis. Diabetes/metabolism research and reviews, 37(8), e3453. https://doi.org/10.1002/dmrr.3453
Fu, Jennifer, et al. "Increased risk of major congenital malformations in early pregnancy use of angiotensin-converting-enzyme inhibitors and angiotensin-receptor-blockers: a meta-analysis." Diabetes/metabolism research and reviews vol. 37,8 (2021): e3453. doi: https://doi.org/10.1002/dmrr.3453
Fu J, Tomlinson G, Feig DS. Increased risk of major congenital malformations in early pregnancy use of angiotensin-converting-enzyme inhibitors and angiotensin-receptor-blockers: a meta-analysis. Diabetes Metab Res Rev. 2021 Nov;37(8):e3453. doi: 10.1002/dmrr.3453. Epub 2021 Apr 13. PMID: 33779043.
Copy Download .nbib Format: NLM
Share it on

Diabetes Metab Res Rev. 2021 Nov;37(8):e3453. doi: 10.1002/dmrr.3453. Epub 2021 Apr 13.

Increased risk of major congenital malformations in early pregnancy use of angiotensin-converting-enzyme inhibitors and angiotensin-receptor-blockers: a meta-analysis.

Diabetes/metabolism research and reviews

Jennifer Fu, George Tomlinson, Denice S Feig

Affiliations

  1. Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  2. University Health Network, Toronto, Ontario, Canada.
  3. Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.
  4. Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada.

PMID: 33779043 DOI: 10.1002/dmrr.3453

Abstract

AIMS: To evaluate the risk of adverse fetal outcomes after exposure to angiotensin converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) in first trimester of pregnancy, by conducting a systematic review and meta-analysis.

MATERIALS AND METHODS: A systematic literature search was conducted using Medline, Embase, Cochrane and PubMed from inception to 25 November 2019. Studies were included if they evaluated pregnancies exposed to ACE-Is or ARBs, reported fetal outcomes, and compared these outcomes with a control group. Pooled odds ratios (ORs) were estimated using inverse variance-weighted random effects model. The protocol was registered with the PROSPERO International Prospective Register of Systematic Reviews (CRD42020160566).

RESULTS: Studies reporting on 6234 pregnancies exposed to ACE-Is or ARBs, 4104 pregnancies exposed to other oral antihypertensives, and 1,872,733 pregnancies without exposure were included in the meta-analysis. ACE-I or ARB exposed pregnancies, compared to non-exposed controls, had higher risk of major congenital malformations (OR 1.82; 95% confidence interval [CI]: 1.42-2.34), cardiovascular malformations (OR 2.50; 95% CI: 1.62-3.87) and stillbirths (OR 1.75; 95% CI: 1.21-2.53). There was no difference in congenital malformations observed between pregnancies exposed to other antihypertensives compared to non-exposed controls (OR 0.96; 95% CI: 0.69-1.33).

CONCLUSIONS: Women exposed to ACE-Is or ARBs during early pregnancy had higher risk of adverse fetal outcomes, including malformations and stillbirths, than non-exposed controls. This increased risk was independent of underlying maternal hypertension, as those exposed to other antihypertensives did not exhibit a higher risk than healthy controls. Women planning for pregnancy using these medications, including those with diabetic nephropathy, should be counselled appropriately.

© 2021 John Wiley & Sons Ltd.

Keywords: angiotensin-converting enzyme inhibitors; angiotensin-receptor antagonists; diabetes mellitus; meta-analysis; pregnancy; pregnancy outcomes

References

  1. Narenberg KA, Zarnke KB, Leung AA, et al. Hypertension Canada’s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018;34(5):506-525. - PubMed
  2. McFarlane P, Cherney D, Gilbert R, et al. “Chapter 29: Chronic kidney disease in diabetes.” Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2018;42(1):S1-S325. - PubMed
  3. Walfisch A, Al-maawali A, Moretti ME, Nickel C, Koren G. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol. 2011;31(6):465-472. - PubMed
  4. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354:2443-2451. - PubMed
  5. Feig DS, Berger H, Donovan L, et al. “Chapter 36: Diabetes and pregnancy.” Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2018;42(1):S1-S325. - PubMed
  6. Li D-K, Yang C, Andrade S, Tavares V, Ferber JR. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ. 2011;343:d5931. - PubMed
  7. Vasilakis-Scaramozza C, Aschengrau A, Cabral HJ, Jick SS. Antihypertensive drugs and the risk of congenital anomalies. Pharmacotherapy. 2013;33(5):476-482. - PubMed
  8. Colvin L, Walters BNJ, Gill AW, et al. The use of angiotensin converting enzyme inhibitors during the first trimester of pregnancy. J Pharmacovigil. 2014;2:129. - PubMed
  9. Bateman BT, Patorno E, Desai RJ, et al. Angiotensin-converting enzyme inhibitors and the risk of congenital malformations. Obstet Gynecol. 2017;129(1):174-184. - PubMed
  10. Hoeltzenbein M, Tissen-Diabaté T, Fietz A-K, et al. Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors - treatment or hypertension related? An observational cohort study. Pregnancy Hypertens. 2018;13:65-71. - PubMed
  11. Sidik K, Jonkman JN. Simple heterogeneity variance estimation for meta-analysis. J R Stat Soc C. 2005;54:367-384. - PubMed
  12. Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med. 2001;20:3875-3889. - PubMed
  13. Schwarzer G. Meta: an R package for meta-analysis. R News. 2007;7(3):40-45. - PubMed
  14. R Core Team. R. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2009. https://www.R-project.org - PubMed
  15. Chintamaneni S, Duan L, Hekimian A, et al. Exposure to angiotensin-converting enzyme inhibitors in pregnancy and the risk of low birth weight and congenital cardiac malformation. J Am Coll Cardiol. 2018;71(11 Suppl):A570. - PubMed
  16. Cournot MP, Vial T, Carlier P, et al. Angiotensin-converting enzyme (ACE) inhibitors during first trimester of pregnancy: a French prospective collaborative study. Drug Saf. 2006;29:911-1010. - PubMed
  17. Caton AR, Bell EM, Druschel CM, et al. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension. 2009;54:63-70. - PubMed
  18. Ahmed B, Tran D, Zoega H, et al. Safety of renin-angiottensin system blockers in early pregnancy: a population-based study. Nephrology. 2018;23:46. - PubMed
  19. Lennestål R, Otterblad Olausson P, Källén B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol. 2009;65:615-625. - PubMed
  20. Porta M, Hainer JW, Hainer JW, et al. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled diabetic retinopathy candesartan trials. Diabetologia. 2011;54:1298-1303. - PubMed
  21. Diav-Citrin O, Shechtman S, Halberstadt Y, et al. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol. 2011;31:540-545. - PubMed
  22. Moretti ME, Caprara D, Drehuta I, et al. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Int J Gynaecol Obstet. 2012;2012:658310. - PubMed
  23. Sato R, Ikuma M, Takagi K, et al. Exposure of drugs for hypertension, diabetes, and autoimmune disease during pregnancy and perinatal outcomes. Medicine. 2015;94(1):e386. - PubMed
  24. Fisher SC, Van Zutphen AR, Werler MM, et al. Maternal antihypertensive medication use and congenital heart defects. Hypertension. 2017;69:798-805. - PubMed
  25. Hoeltzenbein M, Tissen-Diabaté T, Fietz A-K, et al. Pregnancy outcome after first trimester use of angiotensin AT1 receptor blockers: an observational cohort study. Clin Res Cardiol. 2018;107:679-687. - PubMed
  26. Ahmed B, Tran DT, Zoega H, Kennedy SE, Jorm LR, Havard A. Maternal and perinatal outcomes associated with the use of renin-angiotensin system (RAS) blockers for chronic hypertension in early pregnancy. Pregnancy Hypertens. 2018;14:156-161. - PubMed
  27. Duval S, Tweedie R. Trim and Fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455-463. - PubMed
  28. Barr M, Cohen MM. ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection. Teratology. 1991;44:485-495. - PubMed
  29. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev. 2006;82:23-28. - PubMed

Publication Types